Table 1. . Reported results of immune checkpoint blockade in advanced hepatocellular carcinoma (Barcelona Clinic Liver Cancer stage C) patients.
| Trial | Agent | Design and total sample size | ORR% (95% CI) | mDOR months (95% CI) | mTTP months (95% CI) | mOS months (95% CI) | Ref. |
|---|---|---|---|---|---|---|---|
| NCT01008358 | Tremelimumab | II (n = 20) |
17.6 (NR)† | NR | 6.5 (3.95–9.14) | 8.2 (4.6–21.3) | [35] |
| NCT01853618 | Tremelimumab + TACE/RFA | I (n = 32) |
26.3 (9.1–51.2) | NR | 7.4 (4.7–19.4) | 12.3 (9.3–15.4) | [36] |
| NCT01658878 | Nivolumab | I (n = 48) II (n = 214) |
15 (6–28) 20 (15–26) |
17 (6–24) 9.9 (8.3–X) |
3.4 (1.6–6.9) 4.1 (3.7–5.5) |
15 (9.6–20) NR |
[11] |
| NCT02702414 | Pembrolizumab | II (n = 104) |
16.3 (9.8–24.9) | NR | NR | NR | [37] |
| NCT01693562 | Durvalumab | II (n = 40) |
10.3 (2.9–24.2) | NR | NR | 13.2 (6.3–21.1) | [38] |
| NCT02519348 | Durvalumab + tremelimumab | I (n = 40) |
15 (NR) | NR | NR | NR | [39] |
†ORR was assessed by modifed Response Evaluation Criteria in Solid Tumor (RECIST), all studies used RECIST version 1.1.
mDOR: Median duration of response; mOS: Median overall survival; mTTP: Median time to progression; NR: Not reported; ORR: Objective response rate; RFA: Radiofrequency ablation; TACE: Transhepatic arterial chemoembolization.